Assessment of immune potency of SARS-CoV-2 VLP vaccine in mice, enhanced through different adjuvants and liposome complexation

Simple item page
buir.advisorGürsel, İhsan
dc.contributor.authorAbraş, İrem Fatma
dc.date.accessioned2023-09-11T08:59:26Z
dc.date.available2023-09-11T08:59:26Z
dc.date.copyright2023-08
dc.date.issued2023-08
dc.date.submitted2023-09-08
dc.descriptionCataloged from PDF version of article.
dc.descriptionThesis (Master's): Bilkent University, Department of Molecular Biology and Genetics, İhsan Doğramacı Bilkent University, 2023.
dc.descriptionIncludes bibliographical references (leaves 53-59).
dc.description.abstractSARS-CoV-2, emerging in December 2019 in Wuhan, China, led to a swift global pandemic declaration in March 2020, prompting widespread vaccine development. Most vaccines target specific regions, mainly the spike protein. In our lab, we have employed an innovative virus-like particle (VLP) vaccine approach encompassing all four structural proteins of the virus: spike, nucleocapsid, membrane, and envelope. Our study utilizes sterically stabilized cationic liposomes (SSCL) to encapsulate VLPs expressing the Delta variant spike protein, along with various adjuvants: CpG ODN, poly(I:C), and 2’3’-cGAMP. We characterized liposomes using tunable resistive pulse sensing for size and concentration. In C57BL/6 mice, we administered primary and two booster injections on Day 0, Day 15, and Day 73, respectively, collecting blood samples at intervals (Day 14, Day 28, Day 42, Day 72, and Day 90). To assess vaccine impact on mouse humoral immunity, we conducted ELISAs for total IgG, IgG1, and IgG2c antibodies against recombinant Spike and the receptor-binding domain (RBD). IgG titers increased until Day 42, remained stable or slightly decreased on Day 72, and significantly rose on Day 90. We calculated IgG2c/IgG1 ratios, reflecting Th1 immune responses, revealing enhanced cellular immunity potential in groups with adjuvants compared to the VLP-only group. This study underscores the effectiveness of our VLP vaccine strategy in stimulating robust immune responses and opens avenues for further research and development.
dc.description.provenanceMade available in DSpace on 2023-09-11T08:59:26Z (GMT). No. of bitstreams: 1 B162494.pdf: 9978245 bytes, checksum: 53d4eb3e768e00cf76fd89ae0df61061 (MD5) Previous issue date: 2023-08en
dc.description.statementofresponsibilityby İrem Fatma Abraş
dc.embargo.release2024-03-08
dc.format.extentxii, 81 leaves : color illustrations, charts ; 30 cm.
dc.identifier.itemidB162494
dc.identifier.urihttps://hdl.handle.net/11693/113845
dc.language.isoEnglish
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectSARS-CoV-2
dc.subjectVLP
dc.subjectLiposome
dc.subjectCpG
dc.subjectpoly(I:C) 2’3-cGAMP
dc.subjectVaccine
dc.titleAssessment of immune potency of SARS-CoV-2 VLP vaccine in mice, enhanced through different adjuvants and liposome complexation
dc.title.alternativeFarklı adjuvantlar ve lipozom kompleksasyonuyla geliştirilmiş SARS-CoV-2 VLP aşının farelerdeki bağışıklık gücünün değerlendirilmesi
dc.typeThesis
thesis.degree.disciplineMolecular Biology and Genetics
thesis.degree.grantorBilkent University
thesis.degree.levelMaster's
thesis.degree.nameMS (Master of Science)

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
B162494.pdf
Size:
9.52 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.01 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Graduate School of Engineering and Science